(Medical Xpress)—Elderly patients with advanced non small cell lung cancer (NSCLC) who developed a rash within 28 days of receiving the targeted drug erlotinib (Tarceva) survived on average 6.2 months, compared to 4.1 ...
Oct 17, 2012
0
0
(HealthDay) -- For patients with non-small-cell lung cancer (NSCLC) who undergo neoadjuvant platinum-based chemotherapy, tissue platinum concentrations correlate positively with improved outcome, according to a study published ...
Aug 14, 2012
0
0
Scientists from the University of Colorado Cancer Center have once again advanced the treatment of a specific kind of lung cancer. The team has documented how anaplastic lymphoma kinase (ALK) positive advanced non-small cell ...
Jan 19, 2012
0
0
Lung cancer is the leading cause of cancer-related death worldwide. Improved understanding of driver mutations of non-small cell lung cancer (NSCLC) has led to more biomarker-directed treatment for patients with advanced ...
Mar 27, 2024
0
0
A study published in the journal Science Bulletin was led by Yi-Long Wu (Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Chinese Thoracic Oncology Group (CTONG)).
Mar 5, 2024
0
0
More people with non-small cell lung cancer (NSCLC) are likely to benefit from new drugs that target molecular alterations in tumor cells, with less need for chemotherapy, following results of multiple clinical trials reported ...
Oct 18, 2023
0
0
Hyaluronan (HA) accumulation is associated with tumorigenesis and aggressive tumor behavior. In a new study, researchers Jun Gong, Michelle Guan, Haesoo Kim, Natalie Moshayedi, Sejal Mehta, Galen Cook-Wiens, Brent K. Larson, ...
Nov 9, 2022
0
2
The use of Stereotactic Body Radiotherapy (SBRT) for patients with non-small cell lung cancer can reduce treatment disparities between White and Black patients, according to research presented today at the IASLC World Conference ...
Aug 8, 2022
0
2
A study presented today at the IASLC World Conference on Lung Cancer 2022 in Vienna disclosed the clinical-relevant intertumoral heterogeneity of non-small cell lung cancer (NSCLC) driven by MET exon 14 skipping.
Aug 8, 2022
0
5
Using a host immune classifier (HIC) test for patients with non-small cell lung cancer (NSCLC) may provide better predictors of treatment response and improve outcomes, according to research presented today at the International ...
Jan 30, 2021
0
3
